GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Piotroski F-Score

COLL (Collegium Pharmaceutical) Piotroski F-Score : 8 (As of Oct. 08, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Collegium Pharmaceutical has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Collegium Pharmaceutical's Piotroski F-Score or its related term are showing as below:

COLL' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 8

During the past 11 years, the highest Piotroski F-Score of Collegium Pharmaceutical was 8. The lowest was 3. And the median was 5.


Collegium Pharmaceutical Piotroski F-Score Historical Data

The historical data trend for Collegium Pharmaceutical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Piotroski F-Score Chart

Collegium Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 5.00 4.00 7.00

Collegium Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 7.00 8.00 8.00

Competitive Comparison of Collegium Pharmaceutical's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was 20.634 + 31.94 + 27.713 + 19.606 = $99.9 Mil.
Cash Flow from Operations was 74.018 + 73.338 + 61.937 + 67.398 = $276.7 Mil.
Revenue was 136.709 + 149.745 + 144.923 + 145.276 = $576.7 Mil.
Gross Profit was 80.311 + 94.63 + 91.456 + 90.806 = $357.2 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(1213.912 + 1177.578 + 1143.308 + 1114.25 + 1053.388) / 5 = $1140.4872 Mil.
Total Assets at the begining of this year (Jun23) was $1,213.9 Mil.
Long-Term Debt & Capital Lease Obligation was $375.1 Mil.
Total Current Assets was $510.2 Mil.
Total Current Liabilities was $461.7 Mil.
Net Income was 0.457 + -7.199 + -17.426 + 13.007 = $-11.2 Mil.

Revenue was 127.013 + 129.62 + 144.767 + 135.546 = $536.9 Mil.
Gross Profit was 58.839 + 49.789 + 77.402 + 73.826 = $259.9 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(1245.574 + 1200.94 + 1174.131 + 1214.299 + 1213.912) / 5 = $1209.7712 Mil.
Total Assets at the begining of last year (Jun22) was $1,245.6 Mil.
Long-Term Debt & Capital Lease Obligation was $578.0 Mil.
Total Current Assets was $537.3 Mil.
Total Current Liabilities was $435.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Collegium Pharmaceutical's current Net Income (TTM) was 99.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Collegium Pharmaceutical's current Cash Flow from Operations (TTM) was 276.7. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=99.893/1213.912
=0.08229015

ROA (Last Year)=Net Income/Total Assets (Jun22)
=-11.161/1245.574
=-0.00896053

Collegium Pharmaceutical's return on assets of this year was 0.08229015. Collegium Pharmaceutical's return on assets of last year was -0.00896053. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Collegium Pharmaceutical's current Net Income (TTM) was 99.9. Collegium Pharmaceutical's current Cash Flow from Operations (TTM) was 276.7. ==> 276.7 > 99.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=375.088/1140.4872
=0.32888401

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=578.049/1209.7712
=0.4778168

Collegium Pharmaceutical's gearing of this year was 0.32888401. Collegium Pharmaceutical's gearing of last year was 0.4778168. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=510.198/461.717
=1.10500155

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=537.297/435.058
=1.23500085

Collegium Pharmaceutical's current ratio of this year was 1.10500155. Collegium Pharmaceutical's current ratio of last year was 1.23500085. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Collegium Pharmaceutical's number of shares in issue this year was 40.384. Collegium Pharmaceutical's number of shares in issue last year was 42.85. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=357.203/576.653
=0.61944185

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=259.856/536.946
=0.48395183

Collegium Pharmaceutical's gross margin of this year was 0.61944185. Collegium Pharmaceutical's gross margin of last year was 0.48395183. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=576.653/1213.912
=0.47503691

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=536.946/1245.574
=0.43108318

Collegium Pharmaceutical's asset turnover of this year was 0.47503691. Collegium Pharmaceutical's asset turnover of last year was 0.43108318. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Collegium Pharmaceutical has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Collegium Pharmaceutical  (NAS:COLL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Collegium Pharmaceutical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Executives
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021